Nieuwscentrum

jan 29, 2019

Philips’ resultaten vierde kwartaal en jaarresultaat 2018


Philips realiseert de doelstellingen voor het hele jaar, stelt voor het dividend met 6% te verhogen en introduceert een nieuw aandelenterugkoopprogramma van EUR 1,5 miljard
 

Philips behaalt in het vierde kwartaal een omzet van EUR 5,6 miljard, met een groei van de vergelijkbare omzet van 5%; het resultaat uit doorlopende activiteiten steeg naar EUR 723 miljoen en de gecorrigeerde EBITA-marge steeg naar 17,4%

Kerncijfers vierde kwartaal

  • De omzet bedroeg EUR 5,6 miljard, met een groei van de vergelijkbare omzet van 5%
  • De vergelijkbare orderontvangst over het kwartaal nam toe met 10%
  • Het resultaat uit doorlopende activiteiten nam toe naar EUR 723 miljoen, vergeleken met EUR 476 miljoen in het vierde kwartaal van 2017
  • De gecorrigeerde EBITA-marge steeg, ondanks een negatief wisselkoerseffect van 40 basispunten, met 70 basispunten naar 17,4% van de omzet, vergeleken met 16,7% van de omzet in het vierde kwartaal van 2017
  • Het bedrijfsresultaat nam toe naar EUR 769 miljoen, vergeleken met EUR 723 miljoen in het vierde kwartaal van 2017
  • De operationele kasstroom steeg naar EUR 1.293 miljoen, vergeleken met EUR 1.202 miljoen in het vierde kwartaal van 2017; de vrije kasstroom steeg naar EUR 1.019 miljoen, vergeleken met EUR 948 miljoen in het vierde kwartaal van 2017

 

Kerncijfers gehele jaar

  • Sales De omzet steeg naar EUR 18,1 miljard, met een groei van de vergelijkbare omzet van 5%
  • De vergelijkbare orderontvangst nam over het gehele jaar toe met 10%
  • Het resultaat uit doorlopende activiteiten nam toe naar EUR 1.310 miljoen, vergeleken met EUR 1.028 miljoen in 2017
  • De gecorrigeerde EBITA-marge verbeterde met 100 basispunten naar 13,1% van de omzet, vergeleken met 12,1% van de omzet in 2017
  • Het bedrijfsresultaat nam toe naar EUR 1.719 miljoen, vergeleken met EUR 1.517 miljoen in 2017
  • De totale operationele kasstroom bedroeg EUR 1,8 miljard, vergeleken met EUR 1,9 miljard in 2017; de vrije kasstroom bedroeg EUR 984 miljoen, met inbegrip van een uitstroom van EUR 176 miljoen in verband met het verlagen van de risico's van pensioenaansprakelijkheid en een vervroegde aflossing van obligaties, vergeleken met EUR 1.185 miljoen in 2017
  • Voorgesteld wordt het dividend met 6% te verhogen naar EUR 0,85 per aandeel; begin van een nieuw aandelenterugkoopprogramma ter waarde van EUR 1,5 miljard

 

Frans van Houten, CEO

 

“We gingen in de loop van het jaar door met het boeken van vooruitgang en realiseerden in het vierde kwartaal een groei van de vergelijkbare omzet van 5%, met een goede eencijferige groei in onze Diagnosis & Treatment activiteiten, een lage eencijferige groei in onze Personal Health activiteiten, in lijn met onze verwachtingen voor dit jaar, en hogere royalty's op intellectueel eigendom. De groei van vergelijkbare orderontvangst in de Connected Care & Health Informatics activiteiten, die de 10% groei van de vergelijkbare orderontvangst voor de hele Groep bepaalde, ervaar ik als bemoedigend. De gecorrigeerde EBITA-marge steeg met 70 basispunten, ondanks een negatief wisselkoerseffect van 40 basispunten.

 

Over het hele jaar genomen realiseerden we onze doelstellingen, met 5% groei van de vergelijkbare omzet, 100 basispunten verbetering van de gecorrigeerde EBITA-marge, en een vrije kasstroom van EUR 1,2 miljard, afgezien van betalingen in verband met het verlagen van de aansprakelijkheidsrisico's van het pensioenfonds in de USA en premiebetalingen die betrekking hebben op een vervroegde aflossing van obligaties. We zagen een stijgende vraag naar ons assortiment innovatieve producten en oplossingen, wat resulteerde in een 10% groei van de vergelijkbare orderontvangst over het jaar, met wereldwijd een goede groei.

 

Onze voortdurende aandacht voor innovatie in combinatie met ons groeiende orderboek vormt een solide basis voor verdere versterking van onze leidende positie als op de gezondheid gerichte technologieonderneming. Dankzij dit vertrouwen kunnen wij voorstellen het dividend met 6% te verhogen naar EUR 0,85 per aandeel en een nieuw aandelenterugkoopprogramma aankondigen ter waarde van EUR 1,5 miljard.

 

Aangezien Philips blijft geconfronteerd met wereldwijde geopolitieke uitdagingen en marktvolatiliteit, waarvoor we de noodzakelijke acties ondernemen, verwachten we het momentum van onze prestaties in de loop van het jaar te verbeteren. We bevestigen opnieuw onze doelstellingen voor de periode 2017-2020, te weten een groei van de vergelijkbare omzet van 4-6% en een verbetering van de gecorrigeerde EBITA-marge met gemiddeld 100 basispunten per jaar.”

Business segment performance

 

In the quarter, the Diagnosis & Treatment businesses recorded 5% comparable sales growth, driven by double-digit growth in Image-Guided Therapy. Comparable order intake showed a low-single-digit increase on the back of double-digit growth in Q4 2017. The order intake growth was driven by double-digit growth in Diagnostic Imaging. The Adjusted EBITA margin increased to 15.9%, mainly due to growth and operational improvements. For the full year, the Diagnosis & Treatment businesses delivered 7% comparable sales growth and an increased Adjusted EBITA margin of 11.6%.

 

The Connected Care & Health Informatics businesses delivered a double-digit increase in comparable order intake in the fourth quarter, driven by Monitoring & Analytics and Healthcare Informatics. Comparable sales remained flat, with low-single-digit growth in Monitoring & Analytics. The Adjusted EBITA margin decreased to 16.1%, mainly due to lower growth. For the full year, the Connected Care & Health Informatics businesses’ sales were in line with 2017 on a comparable basis, while the Adjusted EBITA margin decreased to 11.1%.

 

The Personal Health businesses delivered comparable sales growth of 3% in Q4 2018, driven by high-single-digit growth in Sleep & Respiratory Care. The Adjusted EBITA margin decreased to 18.6%, reflecting lower growth. For the full year, the Personal Health businesses delivered 3% comparable sales growth and an increase in Adjusted EBITA margin to 16.8%.

 

Philips’ ongoing focus on innovation and strategic partnerships resulted in the following highlights in the quarter:

 

  • NewYork-Presbyterian Hospital selected Philips’ IntelliSpace Enterprise Edition as its in-hospital clinical decision support platform to help address the Quadruple Aim of improved patient experience, better health outcomes, improved staff experience, and lower cost of care across its sites.
  • Continuing the positive momentum of the Diagnostic Imaging business in China, the company received CFDA approval to market its advanced Vereos Digital PET/CT in China. Globally, Philips saw strong demand for its recently launched Ingenia Elition MRI system and Ingenia Ambition MRI system, which enables helium-free operations as well as featuring Compressed SENSE software, a breakthrough acceleration technique speeding up MR exams by up to 50%.
  • Philips entered into multiple new agreements in the US and Europe. For example, the company announced an agreement with County Durham and Darlington NHS Foundation Trust in the UK to provide imaging and cardiology solutions across their sites, further building on the large number of long-term strategic partnerships.
  • Leveraging Philips’ expertise in remote monitoring solutions, the company partnered with Dartmouth-Hitchcock Health in the US to implement Philips’ eICU technology at their hospital sites. Following the success of similar programs across the globe, Dartmouth-Hitchcock Health is the latest health system to incorporate this telehealth model to improve critical care support across multiple sites.
  • Highlighting the success of Philips’ patient-centric product designs in sleep care, Philips has sold more than 10 million DreamWear CPAP masks and cushions in just three years after the Dream Family platform introduction, growing the DreamWear patient interface sales faster than the market.
  • Philips launched an extension to the successful Azurion image-guided therapy platform, setting a new standard in the industry. Azurion with FlexArm includes innovations for optimal visualization across the whole patient in 2D and 3D to simplify and enhance a broad range of procedures. Additionally, Philips announced the enrolment of the first patient in the new Stellarex ILLUMENATE Below-the-Knee (BTK) Investigational Device Exemption (IDE) study in the US.
  • Philips became the first health technology company to have its new CO2 emission targets accepted by the Science Based Targets initiative, a collaboration between the UN Global Compact, the World Resources Institute and the World Wide Fund for Nature aimed at driving ambitious corporate climate action.

 

Cost savings

 

In the fourth quarter, procurement savings amounted to EUR 79 million. Overhead and other productivity programs delivered savings of EUR 56 million, contributing to annual savings of EUR 466 million in 2018.

 

Capital allocation

 

A proposal will be submitted to the Annual General Meeting of Shareholders, to be held on May 9, 2019, to declare a distribution of EUR 0.85 per common share, in cash or shares at the option of the shareholder, against the net income for 2018. 

 

On June 28, 2017, Philips announced its current EUR 1.5 billion share buyback program for capital reduction purposes. Under that program, which was initiated in the third quarter of 2017, Philips repurchased shares in the open market and entered into a number of forward transactions, some of which are yet to be settled in Q2 2019. Further details can be found here.

 

Today, Philips announces a new share buyback program for an amount of up to EUR 1.5 billion. At the current share price, the program represents a total of approximately 46 million shares. Philips expects to start the program in the first quarter of 2019 and to complete it within two years. Updates on the progress of the program will be provided through press releases and further details will be available here.

 

As the program will be initiated for capital reduction purposes, Philips intends to cancel all of the shares acquired under the program. The program will be executed by an intermediary to allow for purchases in the open market during both open and closed periods, in accordance with the EU Market Abuse Regulation.

 

Reporting segment re-alignment as of Q1 2019

 

To further align its businesses with customer needs, Philips has re-aligned its three reporting segments Diagnosis & Treatment, Connected  Care & Health Informatics, and Personal Health. Effective as of January 1, 2019, the most notable changes are the shift of the Sleep & Respiratory Care business from the Personal Health segment to the renamed Connected Care segment, and the shift of most of the Healthcare Informatics business from the Connected Care segment to the Diagnosis & Treatment segment. The Group targets for the 2017-2020 period remain unchanged.

 

Regulatory update

 

Philips has continued to make progress towards fulfilling its obligations under the Consent Decree, which is primarily focused on defibrillator manufacturing in the US. Currently Philips is awaiting feedback from the FDA, which has been postponed due to the recent partial US Government shutdown.

 

Signify

 

Philips’ shareholding in Signify is currently 16.5% of Signify’s issued share capital. With Philips CFO Abhijit Bhattacharya stepping down from the Supervisory Board of Signify as of December 31, 2018, the remaining stake is presented as a financial asset at market value, based on Signify’s stock price. Value adjustments of the retained interest from this date will be recognized in Other Comprehensive Income outside of the Income statement. For Q4 2018, value adjustments of the retained interest are shown within Discontinued operations. Philips reiterates its intention to fully sell down its stake over time.

Quarterly Report

Fourth Quarter and Annual Results 2018 - Quarterly Report

Presentation

Fourth Quarter and Annual Results 2018 - Quarterly Results Presentation

Conference call and audio webcast

A conference call with Frans van Houten, CEO, and Abhijit Bhattacharya, CFO, to discuss the results will start at 10:00AM CET, January 29, 2019. A live audio webcast of the conference call will be available through the link below.

Q4 2018 – Fourth quarter and full year 2018 results conference call audio webcast

 

More information about Frans van Houten and Abhijit Bhattacharya

 

Click here for Mr. van Houten's CV and images

Click here for Mr. Bhattacharya's CV and images


Visit our interactive results hub for more on our financial and sustainability performance over the past quarter, including the latest version of our dynamic Lives Improved world map.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2018 sales of EUR 18.1 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Meer informatieMinder informatie

Forward-looking statements and other important information

Forward-looking statements


This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future Adjusted EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

 

These factors include but are not limited to: global economic and business conditions; political instability, including developments within the European Union, with adverse impact on financial markets; the successful implementation of Philips’ strategy and the ability to realize the benefits of this strategy; the ability to develop and market new products; changes in legislation; legal claims; changes in currency exchange rates and interest rates; future changes in tax rates and regulations, including trade tariffs; pension costs and actuarial assumptions; changes in raw materials prices; changes in employee costs; the ability to identify and complete successful acquisitions, and to integrate those acquisitions into the business, the ability to successfully exit certain businesses or restructure the operations; the rate of technological changes; cyber-attacks, breaches of cybersecurity; political, economic and other developments in countries where Philips operates; industry consolidation and competition; and the state of international capital markets as they may affect the timing and nature of the disposal by Philips of its remaining interests in Signify. As a result, Philips’ actual future results may differ materially from the plans, goals and expectations set forth in such forward-looking statements. For a discussion of factors that could cause future results to differ from such forward-looking statements, see the Risk management chapter included in the Annual Report 2017.

 

Third-party market share data

 

Statements regarding market share, including those regarding Philips’ competitive position, contained in this document are based on outside sources such as research institutes, industry and dealer panels in combination with management estimates. Where information is not yet available to Philips, those statements may also be based on estimates and projections prepared by outside sources or management. Rankings are based on sales unless otherwise stated.

 

Use of non-IFRS information

 

In presenting and discussing the Philips Group’s financial position, operating results and cash flows, management uses certain non-IFRS financial measures. These non-IFRS financial measures should not be viewed in isolation as alternatives to the equivalent IFRS measures and should be used in conjunction with the most directly comparable IFRS measures. Non-IFRS financial measures do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. A reconciliation of these non-IFRS measures to the most directly comparable IFRS measures is contained in this document. Further information on non-IFRS measures can be found in the Annual Report 2017.

 

Use of fair value information

 

In presenting the Philips Group’s financial position, fair values are used for the measurement of various items in accordance with the applicable accounting standards. These fair values are based on market prices, where available, and are obtained from sources that are deemed to be reliable. Readers are cautioned that these values are subject to changes over time and are only valid at the balance sheet date. When quoted prices or observable market data are not readily available, fair values are estimated using appropriate valuation models and unobservable inputs. Such fair value estimates require management to make significant assumptions with respect to future developments, which are inherently uncertain and may therefore deviate from actual developments. Critical assumptions used are disclosed in the Annual Report 2017 and Semi-Annual report 2018. In certain cases independent valuations are obtained to support management’s determination of fair values.

 

Presentation

 

All amounts are in millions of euros unless otherwise stated. Due to rounding, amounts may not add up precisely to totals provided. All reported data is unaudited. Financial reporting is in accordance with the accounting policies as stated in the Annual Report 2017 and Semi-Annual report 2018, unless otherwise stated.

 

References to 'Signify' in this press release relate to Philips' former Lighting segment (prior to deconsolidation as from the end of November 2017 and when reported as discontinued operations), Philips Lighting N.V. (before or after such deconsolidation) or Signify N.V. (after its renaming in May 2018), as the context requires.

 

References to Lumileds in this press release relate to the combined Lumileds and Automotive businesses, which were deconsolidated as from the end of June 2017.

 

Market Abuse Regulation

 

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Meer informatieMinder informatie

Onderwerpen

Contacts

Ben Zwirs

Ben Zwirs

Philips Global Press Office

Tel: +31 6 1521 3446

Martijn van der Starre

Martijn van der Starre

Philips Global Press Office

Tel: +31 6 2847 4617

Business Highlights Q4 2018

Business Highlight: Philips surpasses 10 million DreamWear masks and cushions sold worldwide
Philips surpasses 10 million DreamWear masks and cushions sold worldwide
Business Highlight - Philips launches Azurion with FlexArm to set new standard for the future of image-guided procedures
Philips launches Azurion with FlexArm to set new standard for the future of image-guided procedures
Business Highlights - County Durham and Darlington NHS Foundation Trust and Philips Agree 14 Year Partnership to unlock potential in radiology and cardiology
County Durham and Darlington NHS Foundation Trust and Philips Agree 14 Year Partnership to unlock potential in radiology and cardiology

Deel op social media